CN101611016B - 他拉罗唑代谢物 - Google Patents

他拉罗唑代谢物 Download PDF

Info

Publication number
CN101611016B
CN101611016B CN2007800387031A CN200780038703A CN101611016B CN 101611016 B CN101611016 B CN 101611016B CN 2007800387031 A CN2007800387031 A CN 2007800387031A CN 200780038703 A CN200780038703 A CN 200780038703A CN 101611016 B CN101611016 B CN 101611016B
Authority
CN
China
Prior art keywords
talarazole
hours
metabolites
dose
feces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800387031A
Other languages
English (en)
Chinese (zh)
Other versions
CN101611016A (zh
Inventor
德布拉·巴雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Research Australia Pty Ltd
Original Assignee
Stiefel Research Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Research Australia Pty Ltd filed Critical Stiefel Research Australia Pty Ltd
Publication of CN101611016A publication Critical patent/CN101611016A/zh
Application granted granted Critical
Publication of CN101611016B publication Critical patent/CN101611016B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800387031A 2006-10-17 2007-10-17 他拉罗唑代谢物 Expired - Fee Related CN101611016B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (2)

Publication Number Publication Date
CN101611016A CN101611016A (zh) 2009-12-23
CN101611016B true CN101611016B (zh) 2012-01-25

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800387031A Expired - Fee Related CN101611016B (zh) 2006-10-17 2007-10-17 他拉罗唑代谢物

Country Status (10)

Country Link
US (2) US8188124B2 (https=)
EP (1) EP2114895A4 (https=)
JP (1) JP5343267B2 (https=)
KR (1) KR101419965B1 (https=)
CN (1) CN101611016B (https=)
AU (1) AU2007311026B2 (https=)
BR (1) BRPI0718310A2 (https=)
CA (1) CA2667053C (https=)
MX (1) MX2009004096A (https=)
WO (1) WO2008049027A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
KR101687344B1 (ko) 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
PH12012501686A1 (en) 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
RU2587634C2 (ru) 2010-05-12 2016-06-20 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
EP3372672A1 (en) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CN103154237B (zh) 2010-08-31 2016-03-16 詹森生物科技公司 多能干细胞的分化
PL2853589T3 (pl) 2010-08-31 2018-05-30 Janssen Biotech, Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
EP3450544A1 (en) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endodrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1223654A (zh) * 1996-06-27 1999-07-21 詹森药业有限公司 N－[4－(杂芳基甲基)苯基]－杂芳基胺类化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
IL162533A0 (en) 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US20060205945A1 (en) 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1223654A (zh) * 1996-06-27 1999-07-21 詹森药业有限公司 N－[4－(杂芳基甲基)苯基]－杂芳基胺类化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vincent C. O. Njar, et al.Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.《Bioorganic & Medicinal Chemistry》.2006,第14卷4323-4340. *

Also Published As

Publication number Publication date
AU2007311026B2 (en) 2012-05-17
JP2010506953A (ja) 2010-03-04
CA2667053C (en) 2015-04-28
US8188124B2 (en) 2012-05-29
EP2114895A1 (en) 2009-11-11
CN101611016A (zh) 2009-12-23
US8399495B2 (en) 2013-03-19
CA2667053A1 (en) 2008-04-24
AU2007311026A1 (en) 2008-04-24
MX2009004096A (es) 2009-06-16
US20100292284A1 (en) 2010-11-18
KR101419965B1 (ko) 2014-07-16
JP5343267B2 (ja) 2013-11-13
US20120283204A1 (en) 2012-11-08
KR20090068286A (ko) 2009-06-25
WO2008049027A1 (en) 2008-04-24
BRPI0718310A2 (pt) 2013-11-19
EP2114895A4 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
CN101611016B (zh) 他拉罗唑代谢物
EP4337632B1 (en) Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof
EP1494685B1 (en) Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker
EP2647622B1 (en) Kinesin spindle protein inhibitors and application thereof
US20080114167A1 (en) Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
EP2768308B1 (en) Compounds and anti-tumor nqo1 substrates
KR20210052507A (ko) 간 장애 치료
EP4520752A1 (en) Carebastine salt and use thereof
US9475836B2 (en) Protopanoxadiol derivative, preparation method thereof and application thereof
CN110770244A (zh) 吡啶并咪唑利福霉素衍生物的抗菌剂
US20020132797A1 (en) DNA-cleaving antitumor agents
CN114907331B (zh) 新一代三唑类氘代化合物及其制备方法和用途
CN114907319B (zh) 一种氘代三唑类化合物及其制备方法和用途
US10975099B2 (en) Thiophene compounds for long-acting injectable compositions and related methods
WO2001070217A1 (en) Dna-cleaving antitumor agents
US20250281425A1 (en) Methods for treating skin disorders with a topical composition of bis-(2-chloroethyl)methylamine
WO2022175907A1 (en) Coumarin compounds and a process for preparation thereof
WO2025097160A1 (en) Methods of enhancing levodopa therapeutic efficacy
KR820001304B1 (ko) 펜아탄올아민의 제조방법
Rump et al. 25. Preliminary Pharmacological Investigations of N-amino-diphenyl-hydantoin, a New Hydantoin Derivative with Prolonged Action

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120125

Termination date: 20151017

EXPY Termination of patent right or utility model